|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Refractory or Relapsed Metastatic Soft Tissue Sarcoma
Trial Description Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pazopanib is more effective than a placebo in treating patients with soft tissue sarcoma. This randomized phase III trial is studying pazopanib to see how well it works compared with a placebo in treating patients with metastatic soft tissue sarcoma that has relapsed or not responded to treatment. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned (have an equal chance of being placed) to one of two treatment groups. Patients in group one will receive pazopanib by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients in group two will receive a placebo by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. After finishing treatment, patients will be evaluated every 2-3 months. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations European Organization for Research and Treatment of Cancer
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |